Tag: stock options

Conference call on Thursday, August 7, 2025 at 8:00 a.m. Central Time

FREEHOLD, NJ, Aug. 06, 2025 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE:UMH) (TASE:UMH) reported Total Income for the quarter ended June 30, 2025 of $66.6 million as compared to $60.3 million for the quarter ended June 30, 2024, representing an increase of 10%. Net Income Attributable to Common Shareholders amounted to $2.5 million or $0.03 per diluted share for the quarter ended June 30, 2025 as compared to Net Income Attributable to Common Shareholders of $527,000 or $0.01 per diluted share for the quarter ended June 30, 2024. Normalized Funds from Operations Attributable to Common Shareholders (“Normalized FFO”), was $19.5 million or $0.23 per diluted share for the quarter ended June 30, 2025, as compared to $16.8 million or $0.23 per diluted share for the quarter ended June 30, 2024.

OTTAWA, Ontario, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three and six-month periods ended June 30, 2025. All amounts are in Canadian dollars and reported under IFRS^® Accounting Standards unless otherwise noted.

CALGARY, Alberta, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Total Energy Services Inc. (“Total Energy” or the “Company”) (TSX:TOT) announces its consolidated financial results for the three months ended June 30, 2025.

Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the “Grant Date”), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025.

WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective August 1, 2025, the company granted non-qualified stock options to purchase 134,000 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“ImageneBio”), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio’s recently appointed Chief Executive Officer, on July 28, 2025 that were recommended by the Compensation Committee of its Board of Directors (the “Board”) and approved by the Board. The grant included (i) inducement stock options to purchase 436,080 shares of common stock; and (ii) inducement restricted stock units (“RSUs”) for 153,505 shares of common stock (together, the “Inducement Awards”). The Inducement Awards were granted as inducements material to Dr. Yarema entering into employment with ImageneBio in accordance with Nasdaq Listing Rule 5635(c)(4).